Regulation of KSHV Lytic Switch Protein Expression by a Virus-Encoded MicroRNA: An Evolutionary Adaptation that Fine-Tunes Lytic Reactivation  by Bellare, Priya & Ganem, Don
Cell Host & Microbe
Short ArticleRegulation of KSHV Lytic Switch Protein Expression
by a Virus-Encoded MicroRNA: An Evolutionary
Adaptation that Fine-Tunes Lytic Reactivation
Priya Bellare1,2,3,4 and Don Ganem1,2,3,4,*
1Howard Hughes Medical Institute
2G.W. Hooper Foundation
3Department of Microbiology and Immunology
4Department of Medicine
University of California, San Francisco, San Francisco, CA 94143, USA
*Correspondence: ganem@cgl.ucsf.edu
DOI 10.1016/j.chom.2009.11.008SUMMARY
Herpesviruses encode numerous microRNAs (miR-
NAs), most of whose functions are unknown. The
Kaposi’s sarcoma-associated herpesvirus (KSHV)
encodes 17 known miRNAs as part of its latency
program, suggesting that these RNAs might function
to regulate the latent state. Here we show that one of
these KSHV miRNAs, miRK9*, targets a sequence in
the 30 untranslated region (UTR) of the mRNA encod-
ing the major lytic switch protein (RTA), which
controls viral reactivation from latency. Ectopic
expression of miRK9* impairs RTA synthesis, while
its specific antagonism in latently infected cells
enhances spontaneous lytic reactivation frequency
by 2- to 3-fold. Mutation of the recognition sequence
in the RTA 30UTR abolishes RTA downregulation by
miRK9*. We propose that miRNA targeting of RTA,
while not the primary regulator of the lytic switch,
functions like a safety mechanism on the trigger of
lytic reactivation, preventing stochastic variations in
basal RTA transcription from activating inappro-
priate entry into the lytic cycle.INTRODUCTION
MicroRNAs (miRNAs) are 22 nt single-stranded RNAs that act
posttranscriptionally to regulate the expression of large numbers
of genes in eukaryotic genomes (Filipowicz et al., 2008). It is
estimated that human cells encode more than 400 miRNAs
(Bartel, 2009; Landgraf et al., 2007), and genome-wide transcrip-
tome (Grimson et al., 2007; Lim et al., 2005) and proteome (Baek
et al., 2008; Selbach et al., 2008) profiling has led to estimates
that each miRNA may directly target 100–200 transcripts. These
numbers suggest that the scope and complexity of miRNA
action on the transcriptome are likely to be substantial.
A key determinant of miRNA targeting is the so-called seed
sequence, nucleotides 2–7 of the miRNA (Bartel, 2009). miRNA
targets usually display extensive complementarity to this seed
region, most commonly in their 30UTRs. However, the brevity570 Cell Host & Microbe 6, 570–575, December 17, 2009 ª2009 Elseof the seed means that it alone likely cannot account for all of
the observed specificity of miRNA action—after all, any given
6 nt sequence occurs by chance every few kilobases in the
mammalian genome. It seems likely that additional information
outside the seed contributes to target recognition (Grimson
et al., 2007), but our understanding of such contributions
remains primitive.
Like their hosts, many human and animal viruses also encode
miRNAs (Cullen, 2009; Sullivan and Ganem, 2005); suchmiRNAs
are particularly prominent in herpesviruses (Grundhoff et al.,
2006; Pfeffer et al., 2005; Cai et al., 2005; Dunn et al., 2005;
Grey et al., 2005; Grundhoff et al., 2006; Pfeffer et al., 2005;
Samols et al., 2005; Umbach et al., 2008). Herpesviruses are
large DNA viruses that can support two distinct genetic pro-
grams: latency, in which the viral genome persists in the cell but
with very restricted gene expression, and lytic growth, in which
all viral genes are expressed in a temporally regulated cascade,
leading to death of the cell and progeny virus production.
The Kaposi’s sarcoma-associated herpesvirus (KSHV)
encodes 17 miRNAs, which are derived by processing from 12
pre-miRNAs, all of which are expressed during viral latency
(Cai et al., 2005; Grundhoff et al., 2006; Samols et al., 2005).
Because of their association with latency, it has been speculated
that they may control or modulate the latent-lytic switch. In
keeping with this idea, recent studies in HSV (Umbach et al.,
2008) and HCMV (Murphy et al., 2008) have identified viral
miRNAs that regulate immediate-early regulatory proteins.
However, because of the absence of tractable cell culture-based
models of latency in these viruses, it has not yet been possible to
examine the functional consequences of these interactions for
the latent-lytic decision. Here we describe the identification of
a KSHV miRNA that directly affects latency regulation by modu-
lating the expression of the master regulator of the latent-lytic
switch, the replication and transcription activator (RTA) protein.
RESULTS
Screening for KSHV miRNAs that Target RTA
The default pathway of gene expression in KSHV is latency;
however, latently infected cells can be induced to undergo lytic
replication by a variety of chemical or genetic stimuli. Induction
is controlled by expression of the virus-encoded transcriptionvier Inc.
Figure 1. miRK9* Targets the RTA 30UTR and Inhibits
RTA Function
(A) HEK293 cells were cotransfectedwith a psiCHECK2 vector
in which the 30UTR of RTA was cloned downstream of the
Renilla luciferase gene and individual KSHV-encoded miRNAs
(indicated along the x axis). The Renilla/Firefly ratio was
normalized to a vector that did not contain the 30UTR and to
a negative control miRNA. Bars depict the mean values of
the normalized luciferase activities from triplicate independent
transfections. The difference between the negative control
and miRK9* samples is highly significant (p = 0.003 by t test).
(B) HFF cells latently infected with rKSHV.219 were trans-
fected with individual inhibitors to individual KSHV-encoded
miRNAs (indicated along the x axis). Forty-eight hours later,
spontaneous lytic reactivation was measured as a percent of
RFP-positive cells from a population of healthy, GFP-express-
ing (infected) cells. Mean values of the normalized percent
RFP-positive cells were from five independent transfections
for miRK9* and negative control inhibitors and from two
independent transfections for the other miRNA inhibitors.
The p value between the negative control andmiRK9* samples
is 0.0013 as determined by t test.
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Ectopic expression of RTA triggers reactivation from latency,
and mutational inactivation of RTA ablates reactivation (Lukac
et al., 1998, 1999; Sun et al., 1998; Xu et al., 2005). Because it
resides at a critical node in KSHV’s regulatory network, we
reasoned that it would be a likely target of miRNA regulation.
To determine if any of the KSHV-encoded miRNAs regulate
RTA expression, we cloned the 30UTR of RTA downstream of
the Renilla luciferase gene in a reporter plasmid psiCHECK-2.
Following cotransfection of the plasmid with each of the
individual synthetic KSHV miRNA precursors (or a control
miRNA) into 293 cells, the Renilla luciferase activity in the cells
was measured and normalized to the amount of a control Firefly
luciferase gene bearing its own 30UTR expressed from the same
plasmid. The normalized luciferase value observed in the
presence of a control miRNA was set to 1.0, and the levels of
luciferase generated in the presence of the KSHV miRNAs
were expressed relative to this value. Although there was some
scatter in this assay, only one viral miRNA, miRK9*, consistently
reduced luciferase expression from the LUC/RTA chimera
(Figure 1A); this reduction was highly statistically significantCell Host & Microbe 6, 570–575, December 17, 2009 ª2009 Elsevier Inc. 571t
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30%, is typical of that observed by known
miRNA-target interactions in this assay (see Ziegel-
bauer et al., 2009, and references therein). (The
smaller inhibitions seen with miRs K8, K9, and
K11 in Figure 1A were not reproducible in other
replicates of this experiment.)
Inhibiting miRK9* in Infected Cells
Stimulates Spontaneous Lytic Reactivation
To explore whether miRK9* might target RTA in the
context of an authentic latent viral infection, we set
up a second screen in which 20O-methyl-modified
oligonucleotides antisense to each of the 17 viral
miRNAs were transfected into cells bearing a latent
KSHV genome. The virus genome employed in thisexperiment (rKSHV.219 [Vieira and O’Hearn, 2004]) is genetically
marked, bearing a GFP gene driven by a cellular promoter tha
can be expressed in latently infected cells and an RFP gene
that is under the control of an RTA-responsive lytic promote
and is turned on only in lytically infected cells expressing RTA
Accordingly, if a miRNA targets RTA, transfection with its
cognate inhibitor should upregulate RTA expression and trigge
an increase in RFP-positive cells. To avoid complications from
exogenous (nonphysiologic) chemical inducers, we first looked
at spontaneous lytic reactivation.We tested two cell lines latently
infected with rKSHV.219—these were derived by infection o
human foreskin fibroblasts (HFFs) and SLK endothelial cells
respectively. Following transfection with each miRNA antago-
nist, cells were examined by flow cytometry for GFP and RFP
expression. Figure 1B shows the results for HFF. As can be
seen, only the antagonist of miRK9* appreciably upregulated
RFP expression in this context, nearly tripling the frequency o
spontaneous lytic reactivation (p < 0.005). Similar results were
obtained in SLK cells (data not shown). In a separate experimen
with SLK cells, titration of the miRK9* inhibitor showed there was
up to a 4-fold increase in RFP expression within about 72 hr afte
Figure 2. Inhibition of miRK9* during Lytic Growth Raises Levels
of RTA
HFF/rKSHV.219 cells were transfected with the indicated antagomir, then
induced with butyrate. Extracts prepared at the indicated times
postinduction were immunoblotted for RTA (and for b-actin as a loading
control).
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control inhibitor as well as additional control inhibitors to
miRK4-3p and miRK12 that showed a negligible effect on lytic
reactivation (see Figure S1 available online). These results
strongly indicate that miRK9*, when expressed at physiologic
levels in latency, downregulates RTA.
Although one might expect the effects of miRNAs on RTA
expression to be overwhelmed by strong transcriptional
induction of the target gene, we nonetheless asked if it was
possible to detect effects of miRK9* under conditions of induced
lytic reactivation, again using HFF/rKSHV.219 cells. Sodium
butyrate, an HDAc inhibitor, is a potent chemical inducer of lytic
reactivation. Cells were induced with 10 mM sodium butyrate
and examined at several time points postinfection for RTA
expression by immunoblotting with antisera specific to this
protein. As shown in Figure 2, transfection of the inhibitor to
miRK9* resulted in clearly elevated levels of RTA accumulation
at both 18 and 26 hr postinfection; this elevation was much
reduced at 47 hr, indicating that, as expected, the effect of
miRK9* can be overcome by transcriptional induction of its
target mRNA, which is quite strong by this time (Lukac et al.,
1999). Consistent with this, butyrate-induced cells that had
been pretreated with the miRK9* antagonist display an 35%
increase in RFP expression compared to similarly induced cells
pretreated with the negative control inhibitor (Figure S2). By
contrast, transfection of a mix of inhibitors to miRK9, miRK5,
miRK10a, and miRK10b (which regulate BCLAF-1; Ziegelbauer
et al., 2009) caused the expected modest antagonism of RFP
expression in the butyrate-induced cells (Figure S2).miRK9* Inhibits RTA Protein Expression in a Transient
Transfection Assay
In order to directlymeasure the effect of KSHV-encodedmiRNAs
on RTA expression, transient transfections of the individual
miRNAs together with a plasmid expressing RTA were done in
293 cells. The RTA-expressing plasmid contained genomic
KSHV DNA from the start of the RTA-coding region to the
polyadenylation site of the RTA transcript, expressing a spliced
RTA message that mimics that observed in infected cells.
Following transfections, lysates from the cells were analyzed
by western blotting. We found that of all the miRNAs, miRK9*
most strongly inhibited the expression of RTA (Figure 3); quanti-
fication of these data revealed that miRK9* produced a 45%
reduction in RTA accumulation. (We also noted a significant
inhibition of RTA accumulation in the presence of miRK12, the
basis of which is presently unclear. This miRNA did not score
in the luciferase suppression assay of Figure 1A, nor did its572 Cell Host & Microbe 6, 570–575, December 17, 2009 ª2009 Elseinhibitor score in the lytic induction assay [Figure 1B]. Clearly,
further work will be necessary to determine if miRK12 is truly
a regulator of RTA.)Identifying the Target Site ofmiRK9* in the 30UTR of RTA
A decisive factor influencing targeting by a miRNA is the
presence of a sequence (usually within the target 30UTR) that is
strongly complementary to the miRNA seed region (nucleotides
2–7) (Bartel, 2009). When we searched the 30UTR of RTA mRNA
for seed complementarity, we identified a 6-mer complementary
to positions 2–7 of miRK9*, located near the 30 extremity of the
UTR. Using the luciferase/RTA chimeric reporter, we mutated
the nucleotides in this element that were complementary to
positions 2, 3, and 4 of miRK9* so as to reduce base pairing
with the seed region of the miRNA (Figure 4A). In addition,
we designed a version of miRK9* containing mutations that
compensated for the above changes in the 30UTR so as to
restore Watson-Crick base pairing (Figure 4A). Each wild-type
(WT) or mutant chimera was cotransfected with either a control
miRNA, miRK9*, or the mutant miRK9* bearing the compen-
sating mutations, and luciferase activity was measured (Fig-
ure 4B). As expected, WT miRK9* inhibited luciferase activity
from the WT RTA chimera by about 30% (as also observed in
Figure 1A); however, mutating either the miRNA or the mRNA
target in this region abolished the downregulation (Figure 4B).
Gratifyingly, however, when themutated UTRwas cotransfected
with the seed-complementary mutant miRK9*, the inhibition of
luciferase expression was efficiently rescued (Figure 4B). The
more robust inhibition in the case of the mutated UTR and
miRNA is likely due to the lower base-pairing stability at positions
2, 3, and 4 of the miRNA duplex (A-U instead of C-G), which
allows it to be incorporated more efficiently into the RISC
complex (Schwarz et al., 2003). These observations corroborate
that RTA mRNA is a direct target of miRK9* and define the
predominant molecular target of its action.
To examine the importance of the target site in the authentic
RTA mRNA (as opposed to the reporter constructs employed
above), we cotransfectedmiRK9*with a genomicRTAclone con-
taining either (1) the full-length 30UTR or (2) one in which the
terminal 278 nucleotides of the UTR (including the mapped
miRK9* target sequence) were deleted (30D, Figure 4C, top). We
observed that while miRK9* inhibited RTA expression from the
full-length transcript, it was unable to regulate RTA when the
transcript lacked the mapped target site (Figure 4C, bottom).
When the genomic RTA clone expressing the full-length
transcript was cotransfected with themiRK9* or the seedmutant
version of miRK9*, decrease in RTA protein expression wasvier Inc.
Figure 3. miRK9* Inhibits the Expression of RTA Protein in a Tran-
sient Transfection Assay
A genomic RTA expression vector bearing the full 30UTR sequences was co-
transfected with the indicated individual KSHV-encoded miRNAs; 48 hr later,
lysates were prepared and tested for RTA protein by immunoblotting. As
a loading control, the same blots were probed with antibodies against b-actin.
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again pointing to the importance of the seed sequence in the
miRNA.DISCUSSION
Reactivation from latency is a critical step in the replication and
spread of herpesviruses. In gammaherpesviruses like KSHV and
EBV, latency is the default pathway following de novo infection of
most cell types. Reactivation from latency is required for spread
of virus from cell to cell in an individual, and from person to
person in the population (Ganem, 2006). So a full accounting of
the molecular mechanisms regulating the latent-lytic switch is
important to a nuanced understanding of KSHV biology.
A possible role for miRNAs in such regulation has recently
been suggested by several observations. First, studies in HSV
(Umbach et al., 2008) and HCMV (Murphy et al., 2008) have
identified viral miRNAs that regulate immediate-early genes
that are needed for efficient lytic replication. It has been postu-
lated that these interactions may modulate the latent-lytic
switch; however, neither virus system has tractable in vitro
latencymodels that allow experimental validation of this sugges-Cell Host &tion, which has therefore remained conjectural. Second, in
a recent study of cellular targets of KSHV miRNAs, we found
that targeting of the host BCLAF-1 transcript by miRK5 had clear
effects on the latent-lytic switch—in that case, sensitizing cells to
lytic reactivation. With these precedents in mind, we set out to
screen for viral miRNAs that could regulate the latent-lytic switch
to stabilize latency. Our initial screens focused on RTA, the domi-
nant viral factor controlling this switch.
In earlier work, Murphy et al. (2008) employed a sophisticated
bioinformatic algorithm to predict potential viral targets of
HCMV-encoded miRNAs. Application of this algorithm to
KSHV led them to propose that the 30UTR of KSHV RTA might
be targeted by miRK6-3p. However, this prediction could not
be experimentally validated in our study. Rather, we found that
miRK9* consistently impaired RTA expression, whether from
a chimeric reporter gene or the authentic transcript, and it did
so in the context of an authentic viral infection as well as in trans-
fected cells. Moreover, genetic studies allowed us to unambigu-
ously assign the major target site mediating this interaction.
These observations underscore the difficulties and limitations
of bioinformatic predictions of miRNA targets. We expect that
continuing efforts to experimentally identify and characterize
miRNA target sequenceswill help provide the information neces-
sary to productively refine such algorithms and increase their
predictive power.
We note with interest a recent study of KSHV clinical isolates
that examined their degree of sequence variability in the region
encoding the miRNAs (Marshall et al., 2007). In general, the
KSHV-encoded miRNAs were highly conserved, but the pre-
miRNA for miRK9* showed a somewhat larger number of
sequence polymorphisms thanmost of the other KSHV pre-miR-
NAs. Most of these changes were outside of the mature miRNA;
many may simply be polymorphisms with no phenotypic conse-
quence, but some could theoretically affect processing
efficiency of the pre-miRNA and thereby the levels of mature
miRK9*. Only 1 of 22 sequenced KSHV isolates had a (single)
lesion in the seed sequence of miRK9* (C/U at position 2 of
the miRNA); interestingly, this polymorphism would still support
a G-U base pair at this position with the RTA transcript. Thus,
based on their positions in the miRNA, most of the described
changes would be predicted to have little consequence on
RTA targeting. (The seed-mutated variant, which comes from
a B cell [effusion lymphoma] cell line, might have more substan-
tial effects, especially since this miRNA has numerous other
changes in the mature and pre-miRNAK9* sequence—however,
the significance of this cannot be rigorously discerned in the
absence of the sequence of its cognate RTA gene.)
Finally, it is noteworthy that the phenotype we describe here
for miRK9*—the stabilization of latency by attenuation of RTA
accumulation—is the opposite of that of miRK5, which acts to
enhance susceptibility to lytic reactivation (Ziegelbauer et al.,
2009). As might be predicted from what is known about miRNA
action generally (Baek et al., 2008; Grimson et al., 2007; Sel-
bach et al., 2008), both phenotypes are subtle, consistent
with the idea that miRNA regulation is about the fine-tuning of
gene expression, acting as rheostats (Baek et al., 2008) that
modulate the output of other components of the regulatory
circuitry. We speculate that by promoting the ability to up- or
downregulate susceptibility to lytic reactivation, these latentMicrobe 6, 570–575, December 17, 2009 ª2009 Elsevier Inc. 573
Figure 4. Mapping the Target Site for miRK9*
within the 30UTR of RTA
(A) Predicted base pairing between miRK9* and its puta-
tive site within the 30UTR of RTA is shown. Watson-Crick
base pairings are shown as vertical lines. Mutations
made in the 30UTR and miRK9* are indicated above or
below the WT sequences, respectively.
(B) HEK293 cells were cotransfected with negative control
1 (C1), negative control 2 (C2), miRK9* (K9*), or mutated
miRK9* (K9*m) miRNA together with the luciferase
reporter plasmid containing the WT (W) or mutated (M)
30UTR of RTA. The Renilla/Firefly ratio was normalized to
a vector that did not contain the 30UTR and to a negative
control miRNA. Mean values of the normalized luciferase
activities are from triplicate independent transfections.
P value taken from a t test between C1 and K9* transfected
with WT 30UTR is 0.019, and between C1 and K9*m trans-
fected with mutated 30UTR is 0.014, reflecting statistically
significant values.
(C) (Top) Schematic physical map of the WT and 30D dele-
tion mutant of KSHV RTA region. (Bottom) HEK293 cells
were cotransfected with plasmids encoding WT or 30D
mutant transcript of RTA and with negative control or
miRK9* (K9*) miRNA. Forty-eight hours later, cell lysates
were probed for RTA protein and for b-actin as a loading
control.
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reactivation frequency in response to different environmental
circumstances.
We wish to underscore that miRNA-mediated regulation is not
the primary determinant of the latent-lytic switch—that role
clearly belongs to the transcriptional regulation of RTA expres-
sion. Ablation of miRK9* function results in a discernable
increase in lytic reactivation (2- to 3-fold), but this effect is
small by comparison with inducers of RTA transcription (which
can enhance reactivation 10- to 40-fold). How might a latent
miRNA that targets RTA actually contribute to the regulation
of latency? At first blush, this seems paradoxical, since, accord-
ing to conventional notions of KSHV regulation, the RTA target574 Cell Host & Microbe 6, 570–575, December 17, 2009 ª2009 Elsevier Inc.gene is not expressed in latency. But this is
an oversimplification. Sensitive RT-PCR
measurements indicate that very low basal
levels of expression exist for many inducible
transcripts in the absence of inducing stimuli.
This basal level (sometimes called ‘‘transcrip-
tional noise’’) is subject to considerable
stochastic variation (Blake et al., 2006; Raser
and O’Shea, 2004; Weinberger et al., 2005).
We propose that latent miRK9* expression
serves as a safety mechanism that prevents
stochastic variations in the levels of basal RTA
transcripts from triggering inappropriate lytic
reactivation. The fact that we can observe
modest increases in lytic reactivation in the
presence of antagonists to miRK9* (Figure 1B)
allows an estimate of the frequency of such
inadvertent activation events. But it also reaf-
firms that miRNA-mediated modulation of lytic
reactivation is not the central determinant ofthe latent-lytic switch but a subsequent evolutionary modifica-
tion designed for fine-tuning of its control.EXPERIMENTAL PROCEDURES
Cell Culture, Plasmid Transfections, Luciferase Assays,
and Immunoblotting
Cell culture, plasmid transfections, luciferase assays, and immunoblotting
were carried out as described in the Supplemental Data.
Transfection of miRNA Inhibitors
The KSHV-encoded miRNA inhibitors were from Ambion. HFF and SLK cell
lines expressing the recombinant KSHV (rKSHV.214) were transfected with
the miRNA inhibitors at about 77 and 115 nM, respectively, using Dharmafect
Cell Host & Microbe
KSHV-Encoded miRNA Fine-Tunes Lytic Reactivation1 (Dharmacon). Transfections were done in a 12-well format, and 3 ml of Dhar-
mafect 1 was used for each well. The rest of the procedure was as described
by the manufacturer. Flow cytometry analysis was done 1, 3, or 5 days after
transfection for the SLK cells and 2 days after transfection for the HFF cells.
Themean values of percent RFP-positive cells were derived from at least three
(for SLK cells) or two (for HFF cells) independent transfections. The inhibitors
were transfected into BCBL-1 cells as done before (Ziegelbauer et al., 2009),
except that sequential transfections about 48 hr apart were performed. Before
the second transfection, cells were split to 200,000 cells/mL. Immunofluores-
cence on the cells was done about 48 hr after the second transfection. Mean
values of percent ORF59-positive cells were from duplicate independent
transfections and from at least five different fields within each well.
Immunofluorescence and Flow Cytometry
BCBL-1 cells were washed with PBS, and 200 ml of cells (at a concentration of
200,000 cells/mL) were added to each well of a 6-well slide and allowed to
settle down for 30 min. Cells were then fixed with 4% paraformaldehyde for
30 min and washed with PBS. The rest of the procedure was as done before
(Lukac et al., 1998) using polyclonal antibody to latency-associated nuclear
antigen (LANA, provided by A. Polson) and monoclonal antibody to ORF59
(Advanced Biotechnologies Inc.) or a polyclonal antibody to RTA (Lukac
et al., 1998). Secondary anti-mouse rhodamine and anti-rabbit fluorescein
isothiocyanate (FITC) (Santa Cruz Biotechnology) were used at 1:300. For
flow cytometry, cells were fixed in 4% paraformaldehyde, washed, and their
green and red fluorescencemeasured using a Becton Dickinson FACSCalibur.
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